On Monday, 21st December 2021, the medicine regulator of the European Union have given the authorization to a fifth novel corona virus vaccine for use in the bloc of the 27th member nations, along with granting the authorization for the conditional marketing to the two-dose vaccine made by Novavax, biotechnology in the United States.
The decision of the European Medicines Agency for the recommendation of the authority of the conditional marketing for the corona virus vaccine for the corona virus vaccine for the people, who are more than 18 years age, that should be confirmed by the executive commission of the European, that comes as many countries of European Union that are fighting the increase in the infections amid the concerns about the spread of the new Omicron corona virus variant.
The company ‘Novavax’ said that, it has currently been testing how the covid-19 vaccine shots are going to be holding up against the new Omicron covid-19 variant and just like the several other manufacturers has stared the formulation of an updated version of the vaccine for the purpose of better matching the covid-19 variant in case when it os eventually needed.
The corona virus vaccine shots of Novavax will now join the list of covid-19 vaccines developed by Johnson & Johnson, Moderna, Pfizer and BioNTech in the vaccine armory of the corona virus vaccine. The European Union has also ordered around 100 million doses of the corona virus vaccine developed by Novavax along with an option of more 100 million vaccines shots.
